The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 2×
“Adapted, with permission from (Carmeliet and Jain, 2000) Nature Publishing Group©.”
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“Without doubt, these types of investigations ill shed light on themolecularmechanisms underlying themaligant phenotype of tumor cells (Jones et al., 2008; TCGA, 2008; arsons et al., 2008; Sjoblom et al., 2006).”
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“owever, the constraints defined by the ability of tumor cells to xpress, from a limited set of endogenous pro-angiogenic factors, he angiogenic “bottleneck” constitutes a distinct and important election pressure. For evolving tumors, alternative expression of ngiogenic factors from a limited set of proteins is a relat…”
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Cited by
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
Tang, F., Li, L., & Chen, D. (2012) · Advanced Materials · doi:10.1002/adma.201104763 · Cited by 2,836
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
“antiangiogenic therapy is considered a major anticancer treatment modality”
BackgroundA history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
The Contribution of Angiogenesis to the Process of Metastasis
Bielenberg, D. R., & Zetter, B. R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000138 · Cited by 523
Targeting the ANGPT–TIE2 pathway in malignancy
Huang, H., Bhat, A., Woodnutt, G., & Lappe, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2894 · Cited by 468
Seaman, S., Zhu, Z., Saha, S., Zhang, X. M., Yang, M. Y., Hilton, M. B., Morris, K., Szot, C., Morris, H., Swing, D. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.005 · Cited by 423
JNK signaling in cancer cell survival
Wu, Q., Wu, W., Fu, B., Shi, L., Wang, X., & Kuca, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21574 · Cited by 322
Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
Fang, H., & DeClerck, Y. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0661 · Cited by 284
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells
Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., Lambert, V., Gonzalez, M.-L. A., Colige, A., Rakic, J.-M., Noël, A., Martial, J. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016979 · Cited by 254
Adapala, R. K., Thoppil, R. J., Ghosh, K., Cappelli, H. C., Dudley, A. C., Paruchuri, S., Keshamouni, V, Klagsbrun, M., Meszaros, J. G., Chilian, W. M., et al. (2016) · Oncogene · doi:10.1038/onc.2015.83 · Cited by 153
Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation
Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N. (2017) · Tumor Biology · doi:10.1177/1010428317691001 · Cited by 41
Metadata
- Authors
- Abdollahi, A., & Folkman, J.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 13
- Issue
- 1-2
- Pages
- 16-28
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2110943754
- Cited by
- 233
- References
- 19
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.